Satoshi Muto

Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report

Yuki Owada‐Ozaki, Satoshi Muto, Hironori Takagi et al. · Journal of Thoracic Oncology · 2018 · 205 citations

Medicine, Molecular Medicine, Oncology +17

An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids

Nobuhiko Takahashi, Hirotaka Hoshi, Arisa Higa et al. · Cells · 2019 · 80 citations · Full text

Medicine, Oncology, Pharmacology +16

Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer

Jun Osugi, Takumi Yamaura, Satoshi Muto et al. · Lung Cancer · 2015 · 69 citations

Medicine, Molecular Medicine, Oncology +14

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

Akira Inoue, Kazushi Yoshida, Satoshi Morita et al. · Japanese Journal of Clinical Oncology · 2016 · 69 citations · Full text

Medicine, Oncology, Pharmacology +16

CR3 (CD11b/CD18) expressed by cytotoxic T cells and natural killer cells is upregulated in a manner similar to neutrophil CR3 following stimulation with various activating agents

Satoshi Muto, Václav Větvička, Gordon D. Ross · Journal of Clinical Immunology · 1993 · 61 citations

Life Sciences, Cell Biology, Immunology +12